Literature DB >> 26411741

Outcome in 212 anti-Ro/SSA-positive pregnancies and population-based incidence of congenital heart block.

Amanda Skog1, Linda Lagnefeldt2, Peter Conner3, Marie Wahren-Herlenius1, Sven-Erik Sonesson2.   

Abstract

INTRODUCTION: We investigated the effects of maternal autoimmune disease and fetal congenital heart block (CHB) on pregnancy outcomes in anti-Ro/SSA-positive women and assessed the population-based incidence of isolated CHB.
MATERIAL AND METHODS: One hundred and ninety nine anti-Ro/SSA-positive pregnancies were prospectively followed at our center (2000-2013). Seven fetuses developed atrioventricular block (AVB) II-III. In this period, another 13 anti-Ro/SSA-positive pregnancies were referred for fetal bradycardia, subsequently diagnosed with AVB II-III. Cesarean section rates, gestational age, body measurements at birth, and the incidence of CHB in these 212 pregnancies were analyzed in relation to fetal atrioventricular conduction and maternal diagnosis and compared with data from the Medical Birth Registry on 352,104 pregnancies in the Stockholm County.
RESULTS: The prevalence of maternal systemic lupus erythematosus (SLE) and primary Sjögren's syndrome and the outcomes at birth were similar in normal conduction and AVB I cases. Only 1/20 AVB II-III cases (0/7 in the surveillance group) had a mother diagnosed with SLE, compared with 73/192 in cases with normal conduction or AVB I. Excluding cases with AVB II-III, SLE mothers more frequently delivered by cesarean section (31% vs. 20%, p < 0.05) and had a higher incidence of preterm birth (13% vs. 5.8%, p < 0.05) than the county population. Both SLE and primary Sjögren's syndrome mothers had a fourfold greater rate of growth-retarded babies (10.11% vs. 2.2%, p < 0.001). The incidence of autoantibody-related AVB II-III in Stockholm County was 1/23 300.
CONCLUSION: This study of CHB provides new information on the incidence of CHB and outcome of pregnancy in anti-Ro/SSA-positive women, which has clinical relevance when counseling rheumatic patients considering pregnancy.
© 2015 Nordic Federation of Societies of Obstetrics and Gynecology.

Entities:  

Keywords:  Autoimmune disease; Ro/SSA autoantibodies; congenital heart block; incidence; pregnancy

Mesh:

Substances:

Year:  2015        PMID: 26411741     DOI: 10.1111/aogs.12785

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  10 in total

Review 1.  Progress in the pathogenesis and treatment of cardiac manifestations of neonatal lupus.

Authors:  Peter Izmirly; Amit Saxena; Jill P Buyon
Journal:  Curr Opin Rheumatol       Date:  2017-09       Impact factor: 5.006

2.  Precision medicine for autoimmune disease.

Authors:  Lucienne Chatenoud
Journal:  Nat Biotechnol       Date:  2016-09-08       Impact factor: 54.908

3.  Obstetric and perinatal outcome in anti-Ro/SSA-positive pregnant women: a prospective cohort study.

Authors:  Nuria Martínez-Sánchez; Sergio Pérez-Pinto; Ángel Robles-Marhuenda; Francisco Arnalich-Fernández; María Martín Cameán; Edurne Hueso Zalvide; Jose Luis Bartha
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

4.  Assessment of atrioventricular conduction by echocardiography and magnetocardiography in normal and anti-Ro/SSA-antibody-positive pregnancies.

Authors:  B F Cuneo; S Bitant; J F Strasburger; A M Kaizer; R T Wakai
Journal:  Ultrasound Obstet Gynecol       Date:  2019-11       Impact factor: 7.299

5.  Short and long-term outcomes of children with autoimmune congenital heart block treated with a combined maternal-neonatal therapy. A comparison study.

Authors:  Amelia Ruffatti; Alessia Cerutti; Marta Tonello; Maria Favaro; Teresa Del Ross; Antonia Calligaro; Chiara Grava; Margherita Zen; Ariela Hoxha; Giovanni Di Salvo
Journal:  J Perinatol       Date:  2022-06-18       Impact factor: 3.225

Review 6.  Autoimmune-associated Congenital Heart Block: A New Insight in Fetal Life.

Authors:  Kai-Yu Zhou; Yi-Min Hua
Journal:  Chin Med J (Engl)       Date:  2017-12-05       Impact factor: 2.628

7.  Environmental and lifestyle factors influencing risk of congenital heart block during pregnancy in anti-Ro/SSA-positive women.

Authors:  Sabrina Meisgen; Joanna Tingström; Amanda Skog Andreasson; Sven-Erik Sonesson; Ingrid Kockum; Marie Wahren-Herlenius
Journal:  RMD Open       Date:  2017-09-07

8.  Pregnancy maternal fetal outcomes among pregnancies complicated with atrioventricular block.

Authors:  Kana Wang; Junguo Xin; Guiqiong Huang; Xiaodong Wang; Haiyan Yu
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-10       Impact factor: 3.007

9.  Outcome of Antibody-Mediated Fetal Heart Disease With Standardized Anti-Inflammatory Transplacental Treatment.

Authors:  Wadi Mawad; Lisa Hornberger; Bettina Cuneo; Marie-Josée Raboisson; Anita J Moon-Grady; Jane Lougheed; Karim Diab; Julia Parkman; Earl Silverman; Edgar Jaeggi
Journal:  J Am Heart Assoc       Date:  2022-01-08       Impact factor: 6.106

10.  Type I IFN system activation in newborns exposed to Ro/SSA and La/SSB autoantibodies in utero.

Authors:  Malin Hedlund; Gudny Ella Thorlacius; Margarita Ivanchenko; Vijole Ottosson; Nikolaos Kyriakidis; Linda Lagnefeldt; Joanna Tingström; Allan Sirsjö; Anders A Bengtsson; Emma Aronsson; Kristina Gemzell-Danielsson; Lars Ronnblom; Gunnar Bergman; Alexander Espinosa; Sven-Erik Sonesson; Maija-Leena Eloranta; Marie Wahren-Herlenius
Journal:  RMD Open       Date:  2020-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.